Evidence map›Paper›PMID 41879252›Full record

ArticleVeterinary pathology2026

Immunohistochemical optimization of a panel of antibodies against amyloid precursor protein for immunodetection of axonal injury in neurologic diseases of sheep.

Jim Manavis, Glyn Chidlow, Peter Blumbergs, Ian Jerrett, John Finnie

Abstract read
In one paragraph

Article in Veterinary pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jim ManavisUniversity of Adelaide, Adelaide, SA, Australia.
Glyn ChidlowUniversity of Adelaide, Adelaide, SA, Australia.
Peter BlumbergsUniversity of Adelaide, Adelaide, SA, Australia.
Ian JerrettAgriculture Victoria Research, AgriBio Centre, Bundoora, VIC, Australia.
John FinnieUniversity of Adelaide, Adelaide, SA, Australia.ORCID 0000-0003-2277-1693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyloid precursor protein (APP) is the most sensitive early immunomarker of axonal injury in the brain. Currently, there are several commercially available antibodies to detect axonal spheroids expressing APP. However, immunolabeling of a given molecule can be variable when antibodies are directed to different epitopes. In this study, we optimized a panel of antibodies (22C11, Y188, NAB228, C1/6.1) for labeling APP-immunopositive axonal spheroids in ovine brains and compared the patterns of injury in brains containing spheroids from neurotoxic (clostridial focal symmetrical encephalomalacia [FSE]) and traumatic brain injury. The pattern of axonal spheroid immunolabeling in FSE necrotic foci and trauma-damaged white matter was similar with all 4 antibodies. Only subtle differences in axonal immunolabeling were found probably due to whether the C- or N-terminal fragment of APP was targeted. However, while background labeling with 3 of the antibodies was minimal, there was robust, diffuse labeling of axons due to myelin immunolabeling with the Y188 antibody, which was determined to be specific. Thus, while these antibodies can detect axonal injury with similar efficacy in sheep brains, caution must be taken with Y188 owing to confounding myelin immunolabeling. This study will hopefully serve as a guide for optimal immunodetection of axonal injury in ovine encephalopathies.

Indexed as

Amyloid beta-Protein PrecursorAntibodiesAxonsImmunohistochemistrySheep DiseasesAnimalsBrainSheepAmyloid beta-Protein PrecursorAntibodiesamyloid precursor proteinantibodiesaxonal injurybraincomparative immunohistochemistrymyelin immunostainingsheep

Identifiers

PMID41879252
PMCPMC13534768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.